Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
- 20 July 2005
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 24 (2) , 117-123
- https://doi.org/10.1007/s10637-005-2032-z
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1Journal of Clinical Oncology, 2004
- EGF Receptor As a Therapeutic Target: Patient Selection and Mechanisms of Resistance to Receptor-Targeted DrugsJournal of Clinical Oncology, 2003
- Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancerBritish Journal of Cancer, 2003
- Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracilBritish Journal of Cancer, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Development of ZD1839 in colorectal cancerSeminars in Oncology, 2003
- Epidermal growth factor receptor-targeted therapy in colorectal cancerSeminars in Oncology, 2002
- Epidermal growth factor receptor expression and measurement in solid tumorsSeminars in Oncology, 2002